|1.||Aubry, Alexandra: 10 articles (11/2013 - 04/2004)|
|2.||Mayer, Claudine: 6 articles (08/2014 - 01/2010)|
|3.||Sriram, Dharmarajan: 5 articles (03/2015 - 06/2006)|
|4.||Cambau, Emmanuelle: 5 articles (04/2012 - 04/2004)|
|5.||Yogeeswari, Perumal: 4 articles (03/2015 - 06/2006)|
|6.||Jarlier, Vincent: 4 articles (02/2013 - 04/2004)|
|7.||Nagaraja, Valakunja: 4 articles (03/2008 - 01/2005)|
|8.||Madhavapeddi, Prashanti: 3 articles (02/2015 - 01/2014)|
|9.||Maxwell, Anthony: 3 articles (03/2014 - 01/2005)|
|10.||Piton, Jérémie: 3 articles (11/2013 - 01/2010)|
06/01/2007 - "tuberculosis DNA gyrase would be effective against multi-drug resistant (MDR)-TB, and it could also be effective against fluoroquinolone-resistant M. "
12/01/2015 - "tuberculosis DNA gyrase and molecular insights into its binding mode of action."
03/06/2015 - "tuberculosis GyrB protein to know the interaction profile and structures of compounds 6b and 7d were further substantiated through single crystal XRD."
11/01/2013 - "tuberculosis DNA gyrase, we conducted a series of sequence analyses and structural and biochemical experiments with the isolated GyrA CTD and the holoenzyme. "
04/05/2013 - "tuberculosis-DNA gyrase model with the highest estimated discriminatory power was selected and used afterwards in an additional molecular docking experiment on a mixed combinatorial set of 427 drug-like 6-FQ analogs for which the biological activity values were predicted using a prebuilt counter-propagation artificial neural network model. "
|2.||Bacterial Infections (Bacterial Infection)
02/01/2001 - "The therapeutic use of DNA gyrase inhibitors, mainly quinolone antibacterials, has proven to be a tremendous success story in the treatment of bacterial infections. "
09/01/2000 - "Hokuriku is developing olamufloxacin, a quinolone antibiotic that inhibits DNA gyrase, for the potential treatment of various types of bacterial infection. "
06/01/2001 - "Aventis Pharma AG is investigating a series of novel coumarin DNA gyrase B inhibitors, including RU-79115, as potential treatments for bacterial infections. "
06/01/2010 - "The fluorinated quinolone, ciprofloxacin, is an antibiotic effective for treating bacterial infections by inhibiting the enzyme activity of the DNA type II topoisomerases DNA gyrase and topoisomerase IV. The genes that encode the subunits of DNA gyrase (gyrA and gyrB) and topo IV (par C and parE) contain hotspots within an area known as the quinolone resistance-determining region (QRDR). "
01/01/1990 - "Five quinolone (ofloxacin, cinoxacin, enoxacin, ciprofloxacin, oxolinic acid) and one non-quinolone (coumermycin A1) inhibitors of prokaryotic DNA gyrase used in clinical practice for treatment of bacterial infections were experimentally examinated. "
08/15/2014 - "Minimum inhibitory concentrations (MICs) were determined against a panel of reference strains and clinical isolates of bacteria associated with infection in humans and correlated with the DNA gyrase inhibitory activity. "
03/01/1991 - "These 5-substituted derivatives were compared to the analogous 5-hydrogen compounds for antiinfective activity by using DNA gyrase inhibition, minimum inhibitory concentrations against a variety of bacteria, and in vivo efficacy in the mouse infection model. "
01/01/1989 - "These DNA gyrase inhibitors are established as excellent therapy of urinary infections and of diarrheal disease. "
06/01/2006 - "tuberculosis DNA gyrase with an IC50 of 3.0 microg/mL. The results demonstrate the potential and importance of developing new quinolone derivatives against mycobacterial infections."
08/01/2012 - "These compounds simultaneously inhibit DNA gyrase and Topoisomerase IV at similar nanomolar concentrations, reducing the likelihood of the spontaneous occurrence of target-based mutations resulting in antibiotic resistance, an increasing threat in the treatment of serious infections."
05/01/1998 - "After temperature upshift of the lambda crots plasmid-harboring cells, a Cro repressor-independent control of lambda DNA replication and heat shock resistance of RC are established before the period of DNA gyrase-mediated negative supercoiling. "
09/01/1992 - "As synthesis of the B subunit of DNA gyrase is also sustained during cold shock, we suggest that an increase in the amount of DNA gyrase per cell might occur, which would potentially adapt the cells for growth at reduced temperatures (10 degrees C)."
09/01/1992 - "We identify the A subunit of DNA gyrase as a cold shock protein whose synthesis is sustained following transfer of exponentially growing cultures of Escherichia coli from 37 to 10 degrees C. "
10/04/1996 - "Genetic studies revealed that DNA gyrase seems to catalyze immediate and transient DNA relaxation after Escherichia coli cells are exposed to heat shock (Ogata, Y., Mizushima, T., Kataoka, K., Miki, T., and Sekimizu, K. "
02/01/2012 - "The results presented here suggest that in cells exposed to severe heat-shock stress, DNA supercoiling levels are recovered by the reactivation of DNA gyrase. "
06/22/2001 - "gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity."
02/01/1993 - "Revertant studies and the introduction of a wild-type Escherichia coli DNA gyrase A gene confirmed that ciprofloxacin resistance and chlorhexidine hypersensitivity were not the result of a single mutation. "
02/01/2005 - "In Streptococcus pneumoniae, an H103Y substitution in the ATP binding site of the ParE subunit of topoisomerase IV was shown to confer quinolone resistance and hypersensitivity to novobiocin when associated with an S84F change in the A subunit of DNA gyrase. "
|1.||DNA (Deoxyribonucleic Acid)
|3.||DNA Topoisomerase IV (Topoisomerase IV)
|7.||Bacterial Proteins (Bacterial Protein)